The Therapeutic Double Helix: Clinical Behavior Analysts Are Uniquely Equipped to Support the Rise of Psychedelic Medicine
The field of psychedelic medicine is growing fast. Psilocybin-assisted therapy has received Breakthrough Therapy designation from the FDA. MDMA-assisted treatment for PTSD has moved through clinical trials. Ketamine clinics have proliferated in cities across the country. With this expansion comes an urgent, largely unanswered question (one of many): what happens after the session?
The psychedelic experience itself — vivid, emotionally raw, sometimes mystical — gets most of the attention. However, research shows that the work of lasting change happens in integration: the weeks and months of intentional effort to translate that experience into new ways of living. This is where clinical behavior analysts (CBAs) have something irreplaceable to offer.
The principles underpinning behavior analysis don’t just complement psychedelic medicine. They illuminate it.
The Medicine Session as an Establishing (or Abolishing) Operation
In clinical behavior analysis, a motivating operation (MO) is any environmental variable that alters both the reinforcing value of a consequence and the frequency of behavior that has historically produced that consequence. Establishing operations (EOs) increase the value of a reinforcer. Abolishing operations (AOs) decrease it.
Psychedelic experiences function as extraordinarily powerful motivating operations.
Consider a person who has spent decades numbing emotional pain with alcohol. The reinforcing value of that behavior — the relief, the quiet, the chemical buffer between themselves and their feelings — has been cemented through thousands of repetitions. Now imagine that, during a guided psilocybin session, that person encounters a profound felt sense of interconnection, a visceral confrontation with what they are losing, or a moment of self-compassion so complete it reorganizes how they relate to their own suffering.
In behavioral terms, the psychedelic experience can function as an abolishing operation for the old reinforcer: the alcohol no longer holds the same value. The pull toward numbing is loosened — not by willpower or cognitive reframing alone, but by a shift in the organism’s motivational landscape. Simultaneously, it may function as an establishing operation for new reinforcers: connection, presence, creative expression, somatic awareness. Things that previously held little behavioral pull suddenly matter deeply, possibly because of neurological shifts and medicine experiences that allow the individual to feel, very deeply, that sense of connection, presence, and awareness.
This is not metaphor, but a neurological mechanism.
Clinical behavior analysts understand the real-world shifts that occur as a result of changes in the brain, and vice-versa. We know that MOs are transient — meaning, unless behavior is established and maintained under the new motivational conditions, they tend not to last. Effectively, if we do not take advantage of the more open neural pathways and exhibit healthier or goal-oriented behaviors within the post-medicine window, we will not be given the opportunity to access the reinforcement that comes as a result of those new behaviors.
This is the foundation for why integration is not optional. The window opened by an establishing operation will close. Whether new behavior patterns take root before it does is the clinical question. CBAs are trained to work precisely in this window.
Psychedelic Medicines as a Potent Discriminative Stimulus
A discriminative stimulus (SD) is a stimulus in the presence of which a behavior has been reinforced — a signal that a particular behavior will be met with a particular consequence. The classic example is a green light: it has historically been associated with driving forward safely, so it evokes the behavior.
Psychedelic medicines function as an unusually potent SD.
In the context of a therapeutic session, the substance signals — through its pharmacological and experiential properties — that a different kind of processing is available. Emotional content that has been defended against for years becomes accessible. The internal environment that the psychedelic substance creates is one in which insight, emotional contact, and narrative reorganization have likely been repeatedly “reinforced” (in the colloquial sense, but also in the functional sense).
While I’ve enjoyed learning about the indigenous, spiritual and sacred uses of some of these medicines — psilocybin in particular— the medicine itself is likely not in itself magic (though I can share from experience, it certainly feels as though it is). These medicines are stimuli that reliably shift the probability of a broad class of behaviors: self-disclosure, emotional expression, perspective-taking, memory consolidation, access to the sacred and spiritual, and approach toward rather than avoidance of difficult internal states.
Clinical behavior analysts understand how SDs work — and crucially, how to build generalization away from them. One of the risks in psychedelic-assisted care is that the person’s new way of being becomes stimulus-bound: available only in the presence of the substance or the therapy room. A CBA’s deep expertise in transfer of stimulus control, generalization programs, and building behavior that is maintained by the natural environment is directly applicable here.
The goal is not a person who is transformed during sessions. It is a person who is transformed in daily life.
For example, a question I offer during integration sessions is, “What do you feel capable of doing differently, now that you’ve had this experience?”. Shifting the results of the medicine experience into the daily life of my patients is critical for sustainability. Without this piece, patterns that have been reinforced for years or decades will likely return, a phenomena called behavior drift.
Fresh Snow, New Paths, and the Critical Role of Integration in Preventing Behavior Drift
Emerging neuroscience has produced one of the most compelling frameworks for understanding why psychedelics work: neuroplasticity. Substances like psilocybin, ketamine, and MDMA have been shown to promote synaptogenesis, increase BDNF expression (exercise also does this), and temporarily flatten the hierarchical structure of the default mode network — effectively increasing the brain’s receptivity to change.
The “fresh snow” metaphor captures this well. The neural terrain, ordinarily grooved by years of habitual responding, becomes temporarily open. Old pathways lose their dominance. The tracks laid down in the days and weeks following a psychedelic experience have an outsized opportunity to become the new default.
This is where behavioral science is not just helpful — it is essential. Once behavior begins to change, the next line of treatment is to sustain that change.
Even well-established behavior patterns drift over time without maintenance. This is as true for therapeutic gains as it is for any other skill. The research on long-term outcomes of psychedelic-assisted therapy shows a consistent pattern: those who engage in structured integration maintain their gains. Those who do not often find that the experience fades into memory without fundamentally altering how they live.
The fresh snow can refreeze along the old channels if no one walks new paths through it.
CBA’s are uniquely equipped to address behavior drift because drift prevention is our discipline. We build maintenance into treatment from the start. We monitor for drift through direct observation and data. We design environments — social, physical, behavioral — that support the continuation of new repertoires without requiring constant therapeutic input. We understand that behavior change is not an event. It is a process that requires ongoing programming, fading of supports, and transfer to the natural environment.
From a learning theory standpoint, integration is the deliberate shaping of new behavioral repertoires during a period of heightened neural plasticity. The clinical behavior analyst working in integration is not simply helping to process emotions. They are using behavioral principles — reinforcement, stimulus control, shaping, chaining — to establish new behaviors during the window in which they are most likely to stick.
The psychedelic experience may open the door. Integration — behaviorally sophisticated, data-informed, systematically designed — is what builds the new room.
A Natural Alliance
None of this requires behavior analysts to abandon their empirical foundations or adopt frameworks that conflict with their training. Quite the opposite. The mechanisms by which psychedelic medicines produce change are neurobehavioral mechanisms. Motivating operations shift. Stimulus control is reorganized. New learning occurs under conditions of heightened plasticity. Maintenance depends on the environment that follows.
The field of psychedelic medicine only benefits from creative, ethical and informed practitioners who understand reinforcement contingencies, who can design integration plans with the rigor of behavioral programming, who can fade support systematically rather than leaving clients without scaffolding, and who know how to build behavior that survives the return to ordinary life.
This post is intended for educational purposes and reflects behavioral science perspectives on an emerging area of clinical practice. Psychedelic-assisted therapies should only be pursued within appropriate legal and clinical frameworks.
